Brazil Drug Regulator Rejects Bharat Biotech s Application To Import Covaxin thewire.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewire.in Daily Mail and Mail on Sunday newspapers.
New Delhi, February 5
Pfizer today withdrew its application seeking grant of “emergency use authorization” for its Covid-19 vaccine in India after subject experts at the national regulato
As Vaccine Drive Lags, Serum Institute Sits on 55 Million Covishield Doses Awaiting Government s Call
Why did the Government of India not purchase 50 million doses of Covishield instead of mixing Covaxin and Covishield doses in the vaccination drive?
A paramedic receives a dose of Covishield at the Civil Hospital, Ahmedabad, January 29, 2021. Photo: Reuters/Amit Dave
Health03/Feb/2021
Mumbai: The Serum Institute of India, Pune, is sitting on over 55 million doses of Covidshield and has temporarily halted production of more because there is no offtake from the government, according to sources familiar with the matter. And this delay persists despite a need for doses going even by the government’s own goal of administering 3.33 million per day.
Should India Grant Compulsory Licences to Increase the Supply of Vaccines?
While there currently isn t a shortage of vaccines, compulsory licencing can be a powerful public health tool to work around concerns over insufficient supply of important pharmaceutical products.
A medic show a vial containing doses of Covishield vaccine during a countrywide inoculation drive against the coronavirus, at BSF Hospital in Jammu, Monday, Jan. 25, 2021. Photo: PTI
Trade28/Jan/2021
Indiaâs drug regulator, the Central Drug Standards Control Organisation, approved two coronavirus vaccine candidates â Covishield and Covaxin â for ârestricted useâ in âemergencyâ situations. Covaxin is an indigenous vaccine candidate, developed by Bharat Biotech (Hyderabad), the Indian Council of Medical Research (Delhi) and the National Institute of Virology (Pune).